title: Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
abstract: The adverse effects of regimes in cancer treatment have forced us to change to new targeted therapy options. Understanding these side effects, which can lead to discontinuation of the new therapy strategies, will allow the clinical management of these side effects and result in continuing therapies with effective medications. Bevacizumab, which is an IgG1 antibody against vascular endothelial growth factor, has side effects such as proteinuria, hypertension, venous and arterial thromboembolic events, and hemorrhage. This is the first reported case of dural sinus vein thrombosis, during the treatment with bevacizumab.
authors: Department of Radiation Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey.
authors: Alaattin
authors: A
authors: Ozen
authors: Irfan
authors: I
authors: Cicin
authors: Atakan
authors: A
authors: Sezer
authors: Sernaz
authors: S
authors: Uzunoglu
authors: Mert
authors: M
authors: Saynak
authors: Hakan
authors: H
authors: Genchellac
authors: Hakan
authors: H
authors: Karagol
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy*; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012851:Sinus Thrombosis, Intracranial / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin